Initially identified in melanoma, BRAF mutations have since been detected in multiple solid tumors, including CRC, non-small-cell lung cancer (NSCLC), thyroid carcinoma, biliary tract cancers (BTCs), and gastrointestinal stromal tumors (GISTs), as well as in certain hematologic malignancies and pediatric tumors. This evidence concerns the gene BRAF and non-small cell lung carcinoma.